In situ growth of β-FeOOH nanorods on graphene oxide with ultra-high relaxivity for in vivo magnetic resonance imaging and cancer therapy
In situ growth of β-FeOOH nanorods on graphene oxide with ultra-high relaxivity for in vivo magnetic resonance imaging and cancer therapy
复制标题
具有超高弛豫率的 β-FeOOH 纳米棒在氧化石墨烯上原位生长，用于体内磁共振成像和癌症治疗
DOI：
10.1039/c3tb20234h
复制
发表时间：
2013-01-01
影响因子：
7
通讯作者：
Wang, Jian-Hua
中科院分区：
文献类型：
--
作者：
Chen, Mei-Ling;Shen, Li-Ming;Wang, Jian-Hua
beta-FeOOH 已显示出作为磁共振成像 (MRI) 中的新型造影剂的前景，然而，灵敏和准确的 MR 成像在很大程度上受到其低横向弛豫率 (r(2)) 的限制。在此，我们首次报道了 β-FeOOH 纳米棒在聚乙二醇化氧化石墨烯 (GO) 片上的原位生长，以生产纳米复合材料，例如纳米复合材料。例如，GO-PEG-β-FeOOH。这种纳米复合材料表现出创纪录的超高横向弛豫率（r（2））值303.81 mM（-1）s（-1），也就是说，比迄今为止报道的基于β-FeOOH的MRI造影剂高60倍以上。这有利于其作为体内磁共振成像造影剂的实际应用。 GO纳米复合材料表面的PEG提高了水介质中的胶体稳定性。此外，体外细胞活力测试表明GO-PEG-beta-FeOOH具有最小的细胞毒性。 GO-PEG-beta-FeOOH已用于负载盐酸阿霉素(DOX)，容量为1.35 mg mg(-1)，在Hela细胞凋亡中表现出高效。这些结果表明，GO-PEG-β-FeOOH 为现有的基于纳米颗粒的造影剂提供了一种有效的替代品，用于无创体内 MR 成像和癌症治疗。
beta-FeOOH has shown promise as a new contrast agent in magnetic resonance imaging (MRI), however, sensitive and accurate MR imaging is largely limited by its low transverse relaxivity (r(2)). Herein, for the first time we report in situ growth of beta-FeOOH nanorods onto PEGylated graphene oxide (GO) sheets to produce a nanocomposite, e. g., GO-PEG-beta-FeOOH. This nanocomposite exhibits a record ultra-high transverse relaxivity (r(2)) value of 303.81 mM(-1) s(-1), that is, >60 times higher than those achieved by hitherto reported beta-FeOOH based MRI contrast agents. This well facilitates its practical use as a contrast agent for in vivo MR imaging. PEG on the surface of the GO nanocomposite improved the colloidal stability in aqueous medium. In addition, in vitro cell viability tests demonstrated that GO-PEG-beta-FeOOH has minimal cellular toxicity. GO-PEG-beta-FeOOH has been used for loading doxorubicin hydrochloride (DOX) with a capacity of 1.35 mg mg(-1), which exhibits high efficiency in Hela cell apoptosis. These results indicated that GO-PEG-beta-FeOOH provides an effective alternative to the existing nanoparticle-based contrast agents for non-invasive in vivo MR imaging and cancer therapy.